A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 63 (85), S73-S78
- https://doi.org/10.1046/j.1523-1755.63.s85.18.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney International, 2002
- Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethicsNephrology Dialysis Transplantation, 2002
- Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patientsCurrent Opinion in Nephrology and Hypertension, 2001
- Sevelamer, Ca×P product and vitamin DNephrology Dialysis Transplantation, 2001
- Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in managementAmerican Journal of Kidney Diseases, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Phosphate binders on iron basis: A new perspective?Kidney International, 1999
- Evidence for abnormal calcium homeostasis in patients with adynamic bone diseaseKidney International, 1994
- Hyperphosphatemia: Its Consequences and Treatment in Patients With Chronic Renal DiseaseAmerican Journal of Kidney Diseases, 1992
- Bone Disease and Aluminum: Pathogenic ConsiderationsAmerican Journal of Kidney Diseases, 1985